Head-to-head comparison between 18F-DOPA PET/CT and 68Ga-DOTA-peptide PET/CT in detecting intestinal neuroendocrine tumors: A systematic review and meta-analysis
Clinical Endocrinology Jun 25, 2021
Piccardo A, Fiz F, Bottoni G, et al. - Functional PET tracers are relied upon in the imaging of intestinal neuroendocrine tumors (NETs); both 68Ga-DOTA-peptides and 18F-DOPA PET/CT can be used to study these tumors. Researchers herein sought to compare these two modalities with respect to their sensitivity by performing a meta-analysis of the available data. From PubMed, CENTRAL, Scopus and Web of Science, they identified 636 records; of these, 6 articles published between 2008 and 2021 were finally selected, and 112 intestinal NET patients were included. Findings suggest that in patients with intestinal NETs, both 18F-DOPA PET/CT and 68Ga-DOTA-peptide PET/CT are reliable diagnostic procedures. However, non-negligible difference in favour of 18F-DOPA PET/CT was observed in terms of lesion detection. Hence, they suggest considering the use of 18F-DOPA PET/CT as a first-line molecular procedure in intestinal NETs.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries